Bond.az White LogoBond.az Black Logo

Raymond James Upgrades SM Energy on Oil Strength

Raymond James upgrades SM Energy to Outperform with $55 target on oil strength. SM Energy benefits from Iran war oil price surge.

Henry Walker
ByHenry Walker- Senior Editor
|
0

Raymond James upgraded SM Energy (NYSE:SM) to Outperform from Underperform and set a price target of $55.00.

The firm said SM Energy has been one of the biggest beneficiaries in its coverage universe of the oil price increase following the Iran war. The analyst noted that despite the stock's recent run, a bullish oil outlook relative to the current strip provides upside potential. The stock currently trades at $34.32, near its 52-week high of $34.44, with shares up 90% over the past six months and 85% year-to-date.

SM Energy has reduced absolute debt by approximately $700 million following its merger close. The company expects leverage to fall below 1x by the fourth quarter of 2026, with the possibility of reaching that level earlier under the firm's oil outlook.

The company plans to begin share buybacks in the second quarter of 2026 and continue building free cash flow in the second half of the year. Raymond James said further shareholder upside could be unlocked if the company's balance sheet goals of lower leverage and higher free cash flow remain on track, assuming production performance continues through 2026 and 2027.

SM Energy trades at a 2027 estimated free cash flow to enterprise value ratio of approximately 14% and an enterprise value to EBITDA multiple of approximately 3x. The peer group trades at approximately 9% and 3.5x, respectively. Bond.az analysis indicates the stock remains undervalued.

More News
Today / 09:01
|
899

Citizens Raises Rithm Capital Price Target

Citizens raises Rithm Capital price target to $13.50, highlighting asset growth and a shift to asset management. RITM offers a 11.11% dividend yield.

0
Today / 09:00
|
268

Citizens Raises Relay Price Target to $21

Citizens raises Relay Therapeutics price target to $21 on strong trial data for zovegalisib, with shares up 296%.

0
Today / 08:21
|
408

Jefferies Initiates SAB Biotherapeutics with Buy

Jefferies initiates coverage on SAB Biotherapeutics with a Buy rating and $11 target, focusing on SAB-142 diabetes therapy.

0
Today / 08:03
|
826

UBS Upgrades Packaging Corp. Stock Rating

UBS upgraded Packaging Corp. of America from Neutral to Buy, raising price target to $248. Learn more about PKG stock on Bond.az.

0
Today / 08:02
|
746

BofA Maintains Buy on MakeMyTrip, $60 Target

BofA Securities reiterates Buy on MakeMyTrip (MMYT) with $60 target due to margin expansion and cost control in Q4 results.

0
Today / 07:55
|
540

RBC Capital Cuts Home Depot Target on Housing Woes

RBC Capital cuts Home Depot price target to $340 on housing concerns and higher interest rate outlook. Stock trades near 52-week low.

0
Today / 07:54
|
619

Cantor Fitzgerald Initiates X-Energy with Overweight

Cantor Fitzgerald starts X-Energy with Overweight rating and $38 target, citing strategic position in advanced nuclear.

0
Today / 07:15
|
450

Jefferies downgrades Lanxess stock rating

Jefferies downgraded Lanxess to Underperform with a EUR16 target. Stock at $20.04. Weak chemicals market, Iran conflict impact, and demand risks ahead.

0
Yesterday / 20:01
|
493

Relay Therapeutics Stock Upgrade Boosts Price

Relay Therapeutics stock upgraded by Jones Trading to Buy with $20 target after positive zovegalisib trial data.

0
Yesterday / 19:51
|
929

SandRidge Energy Stock Rating Upgraded to Hold

Freedom Broker upgraded SandRidge Energy to Hold after strong Q1 2026 results. Dividend increased by 8.3% to $0.13 per share.

0
Yesterday / 19:30
|
676

Inuvo PT Cut to $2.50 After Weak Q1

Freedom Broker cut Inuvo's price target to $2.50 after weak Q1 results. Stock fell 20% as the company transitions to IntentKey AI platform. Analysts predict profitability this year.

0
Yesterday / 18:51
|
524

CoreWeave Stock Rises on AI Demand Outlook

Evercore ISI reaffirms Outperform for CoreWeave. AI demand drives positive outlook for the company.

0
...